All In Biotech

Drug Trial Radar · NCT04817618

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy.

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Jul 28, 2021

Primary completion

Jan 29, 2027

Study completion Jan 29, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

Conditions

  • C3G

Interventions

  • PlaceboDrug

    Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

  • iptacopanDrug

    iptacopan 200 mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adult cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection)Time frame: 6 months (double-blind)
  2. Adolescent cohort: Log-transformed ratio to baseline in UPCR (sampled from a 24-hour urine collection)Time frame: 6 months (double-blind)
  3. Change from baseline in log-transformed UPCR at the 12-month visit (both study treatment arms).Time frame: 12 months (double-blind and open-label)
  4. Change in log-transformed UPCR from the 6-month visit to the 12-month visit in the placebo armTime frame: From month 6 to month 12 (open-label)

Locations

88 sites in 19 countries. Site status is shown where the registry gives one.

  • Childrens Hospital Colorado

    Aurora, Colorado · Recruiting

  • Nicklaus Childrens Hospital

    Miami, Florida · Recruiting

  • Georgia Nephrology Research Inst

    Lawrenceville, Georgia · Completed

  • IN University School of Med

    Indianapolis, Indiana · Withdrawn

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • University of Iowa Health Care

    Iowa City, Iowa · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Withdrawn

  • Brigham and Womens Hosp Harvard Med School

    Boston, Massachusetts · Withdrawn

  • Hackensack Uni Medical Center

    Hackensack, New Jersey · Withdrawn

  • Albany Medical Center

    Albany, New York · Withdrawn

  • Col Uni Med Center New York Presby

    New York, New York · Completed

  • Baylor Scott and White Research

    Temple, Texas · Withdrawn

  • University of Wisconsin

    Madison, Wisconsin · Withdrawn

  • Novartis Investigative Site

    Buenos Aires, Argentina · Completed

  • Novartis Investigative Site

    CABA, Argentina · Withdrawn

  • Novartis Investigative Site

    Córdoba, Córdoba Province, Argentina · Withdrawn

  • Novartis Investigative Site

    Edegem, Belgium · Withdrawn

  • Novartis Investigative Site

    Leuven, Belgium · Withdrawn

  • Novartis Investigative Site

    Salvador, Brazil · Withdrawn

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil · Withdrawn

  • Novartis Investigative Site

    Recife, Pernambuco, Brazil · Recruiting

  • Novartis Investigative Site

    Passo Fundo, Rio Grande do Sul, Brazil · Withdrawn

  • Novartis Investigative Site

    Joinville, Santa Catarina, Brazil · Withdrawn

  • Novartis Investigative Site

    Santo André, São Paulo, Brazil · Withdrawn

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Withdrawn

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    London, Ontario, Canada · Completed

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Completed

  • Novartis Investigative Site

    Montreal, Quebec, Canada · Withdrawn

  • Novartis Investigative Site

    Beijing, China · Active not recruiting

  • Novartis Investigative Site

    Beijing, China · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Active not recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Active not recruiting

  • Novartis Investigative Site

    Wuhan, Hubei, China · Withdrawn

  • Novartis Investigative Site

    Prague, Czechia · Completed

  • Novartis Investigative Site

    Lille, France · Completed

  • Novartis Investigative Site

    Marseille, France · Withdrawn

  • Novartis Investigative Site

    Montpellier, France · Withdrawn

  • Novartis Investigative Site

    Paris, France · Completed

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.